NEW YORK, August 14, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), MannKind Corp. (NASDAQ: MNKD), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline PLC (NYSE: GSK) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5727-100free.
--
Tekmira Pharmaceuticals Corp. Research Reports
Shares of Tekmira Pharmaceuticals Corp. (Tekmira) rallied for the second consecutive day on August 11, 2014, following encouraging news from the U.S. Food and Drug Administration (FDA) on its Ebola candidate, TKM-Ebola. As per Tekmira, it has received a verbal confirmation from the FDA on modification of full clinical hold on TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This move allows the potential use of Tekmira's candidate to treat Ebola infected patients. Commenting on FDA modification, Dr. Mark Murray, CEO and President of Tekmira, said "We are pleased that the FDA has considered the risk-reward of TKM-Ebola for infected patients. We have been closely watching the Ebola virus outbreak and its consequences, and we are willing to assist with any responsible use of TKM-Ebola. The foresight shown by the FDA removes one potential roadblock to doing so." The stock has gained 66.78% in the last two trading sessions and ended the August 11, 2014 session at $23.80. The full research reports on Tekmira are available to download free of charge at:
http://www.analystsreview.com/Aug-14-2014/TKMR/report.pdf
--
MannKind Corp. Research Reports
On August 11, 2014, shares of MannKind Corp. (MannKind) settled at $8.53, up 4.92%, after the Company announced that it has entered into a worldwide exclusive licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type I and Type II diabetes. The companies plan to launch Afrezza in the U.S. in Q1 2015. As per the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities, while under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. MannKind will receive an upfront payment of $150 million and potential milestone payments of up to $775 million. In addition, both the Companies are planning to join hands to expand manufacturing capacity to meet global demand, as necessary. The full research reports on MannKind are available to download free of charge at:
http://www.analystsreview.com/Aug-14-2014/MNKD/report.pdf
--
Eli Lilly and Company Research Reports
On August 1, 2014, Eli Lilly and Company (Eli Lilly) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) jointly announced that the U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type II diabetes (T2D). According to Eli Lilly, Jardiance is not for people with type I diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). Commenting on the approval, Enrique Conterno, President, Lilly Diabetes, said, "Today's FDA approval of JARDIANCE provides an exciting new option in the treatment of adults with type 2 diabetes and demonstrates our commitment to these patients, as it marks the third diabetes medicine to emerge from our alliance pipeline." The full research reports on Eli Lilly are available to download free of charge at:
http://www.analystsreview.com/Aug-14-2014/LLY/report.pdf
--
GlaxoSmithKline PLC Research Reports
On July 24, 2014, GlaxoSmithKline PLC (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved Flonase Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient, as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies. Dr. Vidhu Bansal-Dev, Vice President, Research and Development, GSK, said "This approval will bring Flonase® Allergy Relief to consumers in a convenient way at the same dosage strength as found in prescription Flonase. For those with allergies, being able to find simple, effective relief over the counter may mean the difference between a day lost to allergies and a day enjoying their favorite activities." According to the Company, Flonase Allergy Relief will be available OTC in early 2015. The full research reports on GSK are available to download free of charge at:
http://www.analystsreview.com/Aug-14-2014/GSK/report.pdf
--
Cigna Corp. Research Reports
On August 6, 2014, Cigna Corp. (Cigna) announced that David Cordani, President and CEO, will present at the Morgan Stanley Global Healthcare Conference on September 9, 2014 in New York. Cigna informed that its presentation is expected to begin at approximately 1:30 p.m. EDT on the aforesaid date, and interested parties can listen to the presentation free over the Internet via webcast at the Company's website. The full research reports on Cigna are available to download free of charge at:
http://www.analystsreview.com/Aug-14-2014/CI/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
